Yesterday, the Shareholder of Aurinia Pharmaceuticals (AUPH), Chin Kyu Huh, sold shares of AUPH for $1.03M.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.93 and a one-year low of $3.52. The Company has a Price to Book ratio of 7.52.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $25.40, reflecting a -33.1% downside.
The insider sentiment on Aurinia Pharmaceuticals has been negative according to 42 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
